On Monday, H.C. Wainwright adjusted the stock price target for BioLife Solutions (NASDAQ:BLFS), decreasing it to $27 from the previous $29, while keeping a Buy rating on the stock. This change comes ...

BioLife Solutions, Inc. reported past fourth-quarter 2025 sales of US$24.76 million versus US$20.72 million a year earlier, with full-year 2025 revenue of US$96.21 million and a reduced net loss of ...

BioLife Solutions reported third-quarter 2025 results, with revenue of US$28.07 million and net income of US$621,000, also updating its full-year guidance upward after completing the sale of its evo ...

BOTHELL, Wash. - BioLife Solutions, Inc. (NASDAQ: NASDAQ:BLFS), a prominent player in the cell and gene therapy (CGT) market, has finalized the sale of its biostorage subsidiary, SciSafe Holdings, Inc ...

CEO Roderick de Greef highlighted strong quarterly performance, stating that "cell processing revenue increased 33% year-over-year, driving a 31% increase in total revenue for the quarter." He ...

BOTHELL, Wash., Nov. 12, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell ...